Kurz gefasst
Fachartikel in der Zeitschrift Heart Views, 2017. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
• A monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) — has shown that this now FDA-approved drug can reduce LDL-cholesterol levels by 50% to 60% (NEJM JW Cardiol Jun 2014 and N Engl J Med 2014; 370:1811). New data came from FOURIER, a manufacturer-funded outcomes trial of the drug (NCT01764633). • Researchers randomized 27,564 statin-treated patients with atherosclerotic cardiovascular disease (CVD) and LDL levels ≥70 mg/dL (median, 92 mg/dL) to receive subcutaneous evolocumab (140 mg every 2 weeks or 420 mg every month, as the patient preferred) or matching placebo. By 48 weeks of treatment, the drug had reduced LDL levels by 59%, compared with placebo, to a median of 30 mg/dL. • During a median follow-up of 2.2 years, incidence of the primary composite endpoint — cardiovascular death, myocardial infarction (MI), stroke, hospitalization for unstable angina, or coronary revascularization — was significantly lower with evolocumab than with placebo (9.8% vs. 11.3%; hazard ratio, 0.85; 95% confidence interval, 0.79–0.92), as was incidence of the main secondary endpoint of cardiovascular death, MI, or stroke (5.9% vs. 7.4%; HR, 0.80; 95% CI, 0.73–0.88). Findings were consistent across major subgroups. No prominent safety concerns emerged. There was no difference in all-cause mortality.
Zitieren
APA
(2017). Cardiovascular News. Heart Views. https://doi.org/10.4103/1995-705x.206208
Vancouver
Cardiovascular News. Heart Views. 2017. doi:10.4103/1995-705x.206208
BibTeX
@article{euvimed2017,
title = {Cardiovascular News},
journal = {Heart Views},
year = {2017},
doi = {10.4103/1995-705x.206208}
}
EUVIMED